These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 32948843)

  • 21. [Clinical significance of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
    Mi RH; Lu XD; Wei XD; Fan RH; Yin QS; Hu JY; Wang Q; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Sep; 32(9):610-3. PubMed ID: 22338155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia.
    Ma QL; Wang JH; Wang YG; Hu C; Mu QT; Yu MX; Wang L; Wang DM; Yang M; Yin XF; Chen FF; Lu SS; Chen J; Zhu ZJ; Chen SJ; Jin J
    Int J Cancer; 2015 Sep; 137(5):1058-65. PubMed ID: 25523507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
    Balss J; Thiede C; Bochtler T; Okun JG; Saadati M; Benner A; Pusch S; Ehninger G; Schaich M; Ho AD; von Deimling A; Krämer A; Heilig CE
    Leukemia; 2016 Apr; 30(4):782-8. PubMed ID: 26582645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting.
    Ibáñez M; Such E; Cervera J; Luna I; Gómez-Seguí I; López-Pavía M; Dolz S; Barragán E; Fuster O; Llop M; Rodríguez-Veiga R; Avaria A; Oltra S; Senent ML; Moscardó F; Montesinos P; Martínez-Cuadrón D; Martín G; Sanz MA
    J Mol Diagn; 2012 Nov; 14(6):594-601. PubMed ID: 22929312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
    Boissel N; Nibourel O; Renneville A; Gardin C; Reman O; Contentin N; Bordessoule D; Pautas C; de Revel T; Quesnel B; Huchette P; Philippe N; Geffroy S; Terre C; Thomas X; Castaigne S; Dombret H; Preudhomme C
    J Clin Oncol; 2010 Aug; 28(23):3717-23. PubMed ID: 20625116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
    Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
    Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.
    Koszarska M; Bors A; Feczko A; Meggyesi N; Batai A; Csomor J; Adam E; Kozma A; Orban TI; Lovas N; Sipos A; Karaszi E; Dolgos J; Fekete S; Reichardt J; Lehoczky E; Masszi T; Tordai A; Andrikovics H
    Leuk Lymphoma; 2013 May; 54(5):1028-35. PubMed ID: 23039322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical relevance of
    Ferret Y; Boissel N; Helevaut N; Madic J; Nibourel O; Marceau-Renaut A; Bucci M; Geffroy S; Celli-Lebras K; Castaigne S; Thomas X; Terré C; Dombret H; Preudhomme C; Renneville A
    Haematologica; 2018 May; 103(5):822-829. PubMed ID: 29472349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?
    Petrova L; Vrbacky F; Lanska M; Zavrelova A; Zak P; Hrochova K
    Clin Biochem; 2018 Nov; 61():34-39. PubMed ID: 30176240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of IDH1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients.
    Elsayed GM; Nassar HR; Zaher A; Elnoshokaty EH; Moneer MM
    J Egypt Natl Canc Inst; 2014 Mar; 26(1):43-9. PubMed ID: 24565682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Chen EC; Li S; Eisfeld AK; Luskin MR; Mims A; Jones D; Antin JH; Cutler CS; Koreth J; Ho VT; Gooptu M; Romee R; El-Jawahri A; McAfee SL; DeFilipp Z; Soiffer RJ; Chen YB; Fathi AT
    Transplant Cell Ther; 2021 Jun; 27(6):479.e1-479.e7. PubMed ID: 33840625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
    Chaturvedi A; Araujo Cruz MM; Jyotsana N; Sharma A; Yun H; Görlich K; Wichmann M; Schwarzer A; Preller M; Thol F; Meyer J; Haemmerle R; Struys EA; Jansen EE; Modlich U; Li Z; Sly LM; Geffers R; Lindner R; Manstein DJ; Lehmann U; Krauter J; Ganser A; Heuser M
    Blood; 2013 Oct; 122(16):2877-87. PubMed ID: 23954893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
    Zou Y; Zeng Y; Zhang DF; Zou SH; Cheng YF; Yao YG
    Biochem Biophys Res Commun; 2010 Nov; 402(2):378-83. PubMed ID: 20946881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.
    Sasaki M; Knobbe CB; Munger JC; Lind EF; Brenner D; Brüstle A; Harris IS; Holmes R; Wakeham A; Haight J; You-Ten A; Li WY; Schalm S; Su SM; Virtanen C; Reifenberger G; Ohashi PS; Barber DL; Figueroa ME; Melnick A; Zúñiga-Pflücker JC; Mak TW
    Nature; 2012 Aug; 488(7413):656-9. PubMed ID: 22763442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia.
    Berenstein R; Blau IW; Kar A; Cay R; Sindram A; Seide C; Blau O
    J Exp Clin Cancer Res; 2014 May; 33(1):44. PubMed ID: 24887327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen.
    Libura M; Bialopiotrowicz E; Giebel S; Wierzbowska A; Roboz GJ; Piatkowska-Jakubas B; Pawelczyk M; Gorniak P; Borg K; Wojtas M; Florek I; Matiakowska K; Jazwiec B; Solarska I; Noyszewska-Kania M; Piechna K; Zawada M; Czekalska S; Salamanczuk Z; Karabin K; Wasilewska K; Paluszewska M; Urbanowska E; Gajkowska-Kulik J; Semenczuk G; Rybka J; Wrobel T; Ejduk A; Kata D; Grosicki S; Robak T; Pluta A; Kominek A; Piwocka K; Pyziak K; Sroka-Porada A; Wrobel A; Przybylowicz A; Wojtaszewska M; Lewandowski K; Gil L; Piekarska A; Knopinska W; Bolkun L; Warzocha K; Kuliczkowski K; Sacha T; Basak G; Jedrzejczak WW; Holowiecki J; Juszczynski P; Haus O
    Sci Rep; 2021 May; 11(1):10017. PubMed ID: 33976256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Ahn SY; Jung SH; Yang DH; Lee JJ; Park HJ; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Michael S; Minden MD; Kim DD
    Oncotarget; 2017 Jan; 8(5):8305-8314. PubMed ID: 28039446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes.
    Papadopoulou V; Schoumans J; Basset V; Solly F; Pasquier J; Blum S; Spertini O
    Hematology; 2023 Dec; 28(1):2180704. PubMed ID: 36815747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.
    Damm F; Thol F; Hollink I; Zimmermann M; Reinhardt K; van den Heuvel-Eibrink MM; Zwaan CM; de Haas V; Creutzig U; Klusmann JH; Krauter J; Heuser M; Ganser A; Reinhardt D; Thiede C
    Leukemia; 2011 Nov; 25(11):1704-10. PubMed ID: 21647152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of azacitidine in 93 patients with
    Willekens C; Rahme R; Duchmann M; Vidal V; Saada V; Broutin S; Delahousse J; Renneville A; Marceau A; Clappier E; Uzunov M; Rossignol J; Pascal L; Simon L; Micol JB; Pasquier F; Raffoux E; Preudhomme C; Quivoron C; Itzykson R; Penard-Lacronique V; Paci A; Fenaux P; Attar EC; Frattini M; Braun T; Ades L; De Botton S
    Leuk Lymphoma; 2021 Feb; 62(2):438-445. PubMed ID: 33043739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.